Paris-based Metyos has raised €2.3mn in pre-seed funding to improve the lives and health outcomes of chronic kidney disease patients with its biowearable technology. Chronic kidney disease (CKD) affects 10% of the population and is the third fastest-growing cause of death worldwide. It’s also associated with a heavy financial impact on healthcare, with its treatment costing the EU €140bn per year. To fight the disease, Metyos has developed a biowearable sensor in the form of a patch, which provides real-time readings on biomarkers related to CKD. The readings are fed into the startup’s disease management platform, which doctors can use…
This story continues at The Next Web